Development of a qualitative real-time RT-PCR assay for the detection of SARS-CoV-2: A guide and case study in setting up an emergency-use, laboratory-developed molecular assay

Author:

Anahtar Melis N.,Shaw Bennett,Slater Damien,Byrne Elizabeth,Botti-Lodovico Yolanda,Adams Gordon,Schaffner StephenORCID,Eversley Jacqueline,McGrath Graham,Gogakos Tasos,Lennerz Jochen,Marble Hetal Desai,Ritterhouse Lauren L.,Batten Julie,Georgantas N. Zeke,Pellerin Rebecca,Signorelli Sylvia,Thierauf Julia,Kemball Molly,Happi Christian,Grant Donald S.,Ndiaye Daouda,Siddle Katherine J.,Mehta Samar B.,Harris Jason,Ryan Edward T.,Pierce Virginia,LaRocque Regina,Lemieux Jacob E.,Sabeti Pardis,Rosenberg Eric,Branda John,Turbett Sarah E.ORCID

Abstract

ABSTRACTDeveloping and deploying new diagnostic tests is difficult, but the need to do so in response to a rapidly emerging pandemic such as COVID-19 is crucially important for an effective response. In the early stages of a pandemic, laboratories play a key role in helping health care providers and public health authorities detect active infection, a task most commonly achieved using nucleic acid-based assays. While the landscape of diagnostics is rapidly evolving, polymerase chain reaction (PCR) remains the gold-standard of nucleic acid-based diagnostic assays, in part due to its reliability, flexibility, and wide deployment. To address a critical local shortage of testing capacity persisting during the COVID-19 outbreak, our hospital set up a molecular based laboratory developed test (LDT) to accurately and safely diagnose SARS-CoV-2. We describe here the process of developing an emergency-use LDT, in the hope that our experience will be useful to other laboratories in future outbreaks and will help to lower barriers to fast and accurate diagnostic testing in crisis conditions.

Publisher

Cold Spring Harbor Laboratory

Reference16 articles.

1. Association of Public Health Laboratories. Lessons from a Virus: Public Health Laboratories Respond to the H1N1 Pandemic. (2011).

2. RADM Denise M. Hinton, Chief Scientist, Food and Drug Administration. (2020).

3. Scherf (Food and Drug Administration), Uwe. (2020).

4. Primer3—new capabilities and interfaces

5. MGH. Accelerated Emergency Use A Uthorization (Eua) Template For Sars-Cov-2 That Causes Coronavirusdisease (Covid-19) Molecular Testing Of Respiratory Specimens In Clia Certified High-Complexitylaboratories. https://www.fda.gov/media/135658/download (2020).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3